Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03079401|
Recruitment Status : Recruiting
First Posted : March 14, 2017
Last Update Posted : January 23, 2018
Patients under the age of 5, with a diagnosis of hypoplastic left heart syndrome (HLHS), unbalanced atrioventricular canal (uAVC), or borderline left heart who are undergoing staged LV recruitment following bidirectional Glenn (BDG) or undergoing BDG with plans for LV recruitment will be considered for enrollment in this study. Those patients enrolled in the study will be randomized to either the experimental arm or control arm of the study. Those patients randomized to the experimental arm will receive mesenchymal precursor cells (MPCs) injected directly into the LV endocardium during their LV recruitment or BDG procedure. Those patients randomized to the control arm will receive normal standard of care during their procedure with no injection of MPCs.
It is believed that injection of MPCs will help improve the chances of those patients with single ventricle or borderline left ventricle being converted to biventricular circulation which could improve quality of life and longevity over palliation.
|Condition or disease||Intervention/treatment||Phase|
|Hypoplastic Left Heart Syndrome Atrioventricular Canal||Biological: MPC; rexlemestrocel-L||Phase 1 Phase 2|
This is a prospective, single center, safety and feasibility, blinded, randomized trial to evaluate the use of MPCs in children with complex cardiac anatomy requiring surgical repair. Patients scheduled to undergo bidirectional Glenn (BDG) with future plans for LV recruitment, or patients with a history of BDG who are currently scheduled to undergo LV recruitment will be eligible.
Twenty-four subjects will be enrolled, 12 to the MPC treatment arm and 12 to the control arm following a 1:1 randomization schema. Randomization will be stratified according to surgeon to assure random distribution of subjects by surgeon. Families, the biostatistician, all clinical staff outside the operating room, and research staff completing data analysis will be blinded to randomization assignment. The PI, operating room staff, and research staff assisting with delivery will be unblinded to the randomization assignment. Families will be made aware of their randomization assignment once all subjects have completed their study Visit 4. Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG. Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
All cardiac tissue acquired as part of a clinically indicated procedure will be collected on enrolled subjects. Most of the tissue sample will be analyzed at the time of collection (histology and H+E stain); the remainder will be banked for potential future testing.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle|
|Actual Study Start Date :||November 27, 2017|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2021|
Experimental: Treatment Arm
Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.
MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL.
Biological: MPC; rexlemestrocel-L
MPCs will be injected into the patient's myocardium during planned surgical procedures.
Other Name: Allogeneic Mesenchymal Precursor Cell
No Intervention: Control Arm
Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
- Safety- Incidence of severe adverse events [ Time Frame: 24 months ]Subjects will be SAE free for 24 months following injection of MPCs (in comparison of treatment arm to control arm.
- Safety- Absence of PRA status change or local inflammation [ Time Frame: 24 months ]Subjects will be free from Panel Reactive Antibody (PRA) status change for 24 months following injection of MPCs (in comparison of treatment arm to control arm). If there is a PRA of >5%, a donor specific antibody test will be completed,
- Efficacy- rate of biventricular conversion [ Time Frame: 12 months ]Rate of those who are successfully converted to biventricular conversion in the treatment group compared to the control group.
- Efficacy- improvement of LV end diastolic pressure [ Time Frame: 12 months ]Rate of those who have improvement in these measurements in the treatment group compared to the control group.
- Efficacy- improvement of LV mass/volume ratio [ Time Frame: 12 months ]Rate of those who have improvement in these measurements in the treatment group compared to the control group.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03079401
|Contact: Breanna Piekarski, RN, BSNemail@example.com|
|United States, Massachusetts|
|Boston Children's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Breanna Piekarski, RN, BSN 617-919-4457 firstname.lastname@example.org|
|Principal Investigator: Sitaram M Emani, MD|
|Principal Investigator:||Sitaram M Emani, MD||Boston Children’s Hospital|